Prime Medicine, Inc.

Historical 13F Holders

Symbol
PRME
CUSIP
74168J101
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 74168J101 since 12/18/2024, newest first.

Filer % of Class Filed
T. Rowe Price Investment Management, Inc. 13G/A Amendment 1 3.3% 2/17/2026
Event 12/31/2025
T. Rowe Price Investment Management, Inc. 13G 5.3% 11/14/2025
Event 9/30/2025
GV 2019, L.P. 13G/A Amendment 3
12.3% 11/12/2025
Event 9/30/2025
FMR LLC 13G/A Amendment 4
3.8% 11/5/2025
Event 9/30/2025
ARCH Venture Fund XII, L.P. 13D/A Amendment 2
10.4% 8/11/2025
Event 8/7/2025
Newpath Partners, L.P. 13G/A Amendment 1
4.7% 2/14/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 16 455 k $1.40 M
2026 Q2 196 107 M $551 M
2026 Q1 199 98.6 M $343 M
2025 Q4 196 98.2 M $341 M
2025 Q3 184 92.5 M $512 M
2025 Q2 129 58.7 M $145 M
2025 Q1 132 60.4 M $120 M
2024 Q4 138 64.3 M $188 M
2024 Q3 123 68.7 M $266 M
2024 Q2 129 69.1 M $355 M
2024 Q1 123 67.1 M $470 M
2023 Q4 113 49.0 M $434 M
2023 Q3 86 49.5 M $472 M
2023 Q2 80 46.1 M $676 M
2023 Q1 79 41.7 M $512 M
2022 Q4 69 41.4 M $770 M